Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

 
• By Joseph Haas
Dominoes
Intercept followed a second CRL by announcing its exit from NASH R&D • Source: Shutterstock

More from New Products

More from Scrip